Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Active, not recruiting Not applicable

Effectiveness of Coordinated Care to Reduce the Prolonged Disability Risk Among Patients Suffering From Low Back Pain in Primary Care

NCT04826757 · tracked via the Priya Life Science France tracker
Phase
Not applicable
Started
2022-09-21
Last updated
2026-07-13

Condition(s) studied

Low Back Pain

Investigational drug(s) / intervention(s)

Coordinated care

Coordinated care: Coordinated care between general practioners; physiotherapists and occupational health services. Early contact with occupational health service by the general practioner and use of occupational retention tool Active physiotherapy (Individual active, intensive and regular rehabilitation program with 15 sessions of 1 hour, at a rate of 2 or 3 sessions per week)

Study summary

Common low back pain affects about 23% of general population and can be associated with psychosocial difficulties and prolonged inability to work. Its management in France mainly depends on general practioners, and sometime on physiotherapists.

A coordinated care between general practioners, physiotherapists and occupational health services would help to improve the care pathway for patients and health professionals.

The main objective is to assess the impact of coordinated primary care and deployed at the territories' level, in subacute or acute recurrent low back pain patients in comparison with the standard care.

Eligibility

Sex
ALL
Min age
18 Years
Max age
60 Years
Healthy volunteers
No
Inclusion Criteria: * Patient consulting an investigator GP for subacute low back pain or acute recurrent low back pain * Patient with occupational activity (including sick leave) * Patient depending of occupational health service * Obtaining the signature of the consent to participate in this trial * Patient Registered with social security scheme Non-inclusion Criteria: * Specific low back pain (fracture, infection, osteoporosis, inflammatory disease, tumor) * Low back pain with sciatic, cruralgia * Contraindication to active reeducation * Impossibility to follow up during 12 months * Patient planning to retire within the 12 months following the enrollment * Disability to write or read french * Adult patient protected under the law (guardianship), * Pregnant, breastfeeding or parturient women * Persons deprived of their liberty by judicial or administrative decision * Persons subject to legal protection measures * Persons unable to consent * Persons on coercion psychiatric care * Physiotherapy by a physiotherapist who don't participate in this trial

Primary outcome measure(s)

  • Perceived inability at 1 year — Enrollment to 12 months follow up
    Ratio of patient presenting improvement equal or above 4 points of Roland Morris Disability Questionnaire. The minimum value of Roland Morris Disability Questionnaire is 0 and the maximun value is 24. A higher score mean worse outcome

Trial sites (20)

FacilityCityRegionStatus
Cluster Bonchamp Bonchamp-lès-Laval France
Cluster Vaunoise Breteil France
Cluster BRULON Brûlon France
Cluster Château Gontier Château-Gontier France
Cluster Châteauneuf sur Sarthe / Morannes Châteauneuf-sur-Sarthe France
Cluster Clisson Clisson France
Cluster Conlie Conlie France
Cluster Craon Renaze Cosse Craon France
Cluster Entrammes Laval Entrammes France
Cluster Roche sur Yon La Roche-sur-Yon France
Cluster Chantenay Nantes France
Cluster Dinan / Quévert / Plouasne Quévert France
Cluster Rennes Beauregard Rennes France
Cluster Rennes Villejean Rennes France
Cluster Les Collines Roquefort-les-Pins France
Cluster St Florent, Mauges, Possonnière Saint-Florent-le-Vieil France
Cluster Savenay Savenay France
Cluster SEGRE Segré France
Cluster Angers- Trélazé Trélazé France
Cluster Vence Vence France
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT04826757 on ClinicalTrials.gov ↗ ← All trials in France